8-K: Kineta's VISTA-101 Trial Shows Promising Safety and Biomarker Data for KVA12123

Kineta's Phase 1/2 clinical trial of KVA12123 in advanced solid tumors demonstrates a favorable safety profile and dose-proportional induction of pro-inflammatory biomarkers.

Summary

• Kineta, Inc. announced an update on its Phase 1/2 VISTA-101 clinical trial for KVA12123, an immunotherapy targeting VISTA, in patients with advanced solid tumors.
• The trial has completed the first four monotherapy dose levels and the initial combination cohort with Merck's KEYTRUDA, with no dose-limiting toxicities observed.
• KVA12123 showed dose-proportional increases in pro-inflammatory biomarkers, which are essential for anti-tumor activity.
• A total of 18 patients have been dosed, with 15 in monotherapy cohorts receiving doses from 3 to 100 mg, and 3 in a combination cohort receiving 30 mg of KVA12123 with 400mg of pembrolizumab.
• The study is progressing on schedule, with full enrollment of the Phase 1 portion expected by April 2024.
• The primary goals of the study are to assess safety and tolerability and to determine the recommended Phase 2 dose.

Sentiment

Score: 8

Explanation: The document presents positive safety and biomarker data for KVA12123, indicating a promising start to the clinical trial. The lack of dose-limiting toxicities and CRS is encouraging. The study is progressing on schedule, and management commentary is optimistic. However, there are still risks associated with drug development and future funding.

Positives

• KVA12123 was well-tolerated at all doses tested, with no dose-limiting toxicities or cytokine-related adverse events.
• The drug showed a dose-proportional increase in pro-inflammatory biomarkers, which are crucial for anti-tumor activity.
• There was no evidence of cytokine release syndrome (CRS) at any dose level.
• KVA12123 achieved high VISTA receptor occupancy, indicating effective target engagement.
• The study is progressing on schedule, with Phase 1 enrollment expected to complete by April 2024.

Risks

• The company's ability to secure sufficient capital to support future operations and complete clinical trials is a risk.
• There are risks associated with predicting the time and cost of drug development.
• Clinical trial results may not be predictive of future outcomes.
• There is a risk of delays or cessation of ongoing or planned clinical trials.
• The market acceptance and clinical utility of Kinetas product candidates are not guaranteed.
• The company faces risks related to competition, government regulations, and intellectual property protection.

Future Outlook

Kineta anticipates releasing additional monotherapy clinical efficacy data and initial combination clinical data in Q2 2024. The company expects to fully enroll the Phase 1 portion of the trial by April 2024.

Management Comments

• Shawn Iadonato, Ph.D., Chief Executive Officer of Kineta, stated that the efficacy-related biomarker data demonstrates on-target activity of KVA12123.
• Shawn Iadonato also mentioned that the safety profile supports advancing to higher doses in the monotherapy and combination cohorts.
• Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, expressed pleasure with the compelling safety data and lack of CRS-associated cytokine induction.

Industry Context

This announcement is significant in the immuno-oncology space, as it provides an update on a novel VISTA-blocking immunotherapy. The positive safety and biomarker data could position KVA12123 as a potential competitor to other checkpoint inhibitors, particularly in tumors with high VISTA expression. The combination with KEYTRUDA also aligns with the trend of combining immunotherapies to enhance efficacy.

Comparison to Industry Standards

• The document notes that competitive therapies targeting VISTA have shown poor monotherapy activity or induced cytokine release syndrome (CRS) in human trials, which KVA12123 appears to avoid.
• The combination of KVA12123 with pembrolizumab (KEYTRUDA) is a common strategy in immuno-oncology, as pembrolizumab is a well-established anti-PD-1 therapy.
• The reported greater than 90% VISTA receptor occupancy at the 30 and 100 mg doses is a positive indicator of target engagement, which is a key factor in the success of immunotherapies.
• The dose-proportional increase in pro-inflammatory biomarkers is consistent with the desired mechanism of action for this type of therapy.

Stakeholder Impact

• Shareholders may view the positive clinical trial update favorably, potentially increasing investor confidence.
• Patients with advanced solid tumors may benefit from the development of a new immunotherapy option.
• Employees of Kineta may be encouraged by the progress of the clinical trial.
• The company's partners and collaborators may see this as a positive development in the drug's progress.

Next Steps

• The company will continue to enroll patients in the Phase 1 portion of the trial, aiming for full enrollment by April 2024.
• Kineta will initiate dosing of the 300 mg monotherapy and 100 mg in combination with pembrolizumab cohorts.
• The company plans to release additional monotherapy clinical efficacy data and initial combination clinical data in Q2 2024.

Key Dates

Keywords

KVA12123, VISTA, Immunotherapy, Solid Tumors, Clinical Trial, Phase 1/2, Biomarkers, Oncology, KEYTRUDA, Pembrolizumab